Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
143 hedge funds and large institutions have $839M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 54 increasing their positions, 50 reducing their positions, and 24 closing their positions.
16% more call options, than puts
Call options by funds: $33.5M | Put options by funds: $28.9M
8% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 50
5% less funds holding
Funds holding: 150 → 143 (-7)
5% less capital invested
Capital invested by funds: $885M → $839M (-$46.5M)
21% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 24
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wolverine Trading
Chicago,
Illinois
|
+$28.5M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$10.1M |
| 3 |
AC
Armistice Capital
New York
|
+$6.57M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$4.4M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$25.5M |
| 2 |
Millennium Management
New York
|
-$7.69M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$6.31M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$4.51M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$2.95M |
DCPH Hedge Fund Activity: Q4 2022 in Review
143 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q4 2022, worth a combined $839M — down 5.3% from $885M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of DCPH and 19 opened new positions — a net loss of 5 holders — while 50 trimmed existing stakes and 54 added.
The largest buyer was Wolverine Trading, opening a new position worth an estimated $28.5M. The largest seller was Goldman Sachs, cutting an estimated $25.5M.
- 143 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q4 2022, down from 150 in Q3 2022.
- Funds reported $839M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q4 2022, down 5.3% quarter-over-quarter.
- 19 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q4 2022 and 24 closed out, a net change of -5 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q4 2022 was Wolverine Trading, an estimated $28.5M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q4 2022 was Goldman Sachs, an estimated $25.5M sold.
Based on aggregated 13F filings for Q4 2022.